Envista Holdings (NVST)
NYSEHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-09
$26.42-1.45%
Close 2026-09-09 · 1-day change
NYSEHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-09
Broken: Primary pillar broken — Core sales revenue growth >=9.5% YoY: rev +5.0% vs 9.5%.
Envista grows core sales about 9.5% yearly. Profit margins improve with adjusted EBITDA rising 25% year-on-year. The company returns capital through steady share buybacks. Free cash flow guidance is maintained despite short-term volatility.
Cash flow weakened sharply in Q1 2026 with negative free cash flow. Operating cash flow volatility may pressure financial flexibility. Revenue growth could slow below analyst expectations amid soft guidance.
The price is about 19% below our fair value near $34. Analysts expect roughly 4% revenue growth, while we see upside from current 9.5% core growth. The market prices in moderate growth and stable margins.
Breaks if: Adjusted EBITDA falls below $79 million next year
Breaks if: YoY revenue growth falls below 4% next year
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on revenue growth and improving margins. The current thesis is supported by strong financial performance and management's consistent delivery on key priorities.
The market appears to have priced in a justified valuation, suggesting that expectations are somewhat aligned with the company's recent performance. However, NVST is considered expensive compared to its peers, indicating that some premium is built into its valuation.
Management has shown strong execution in increasing revenue and improving operating income and cash flow. While there is a low probability of missing earnings expectations, recent trends show a decline in earnings surprises, which could pose a risk.
The thesis hinges on maintaining momentum in the healthcare sector, especially if key competitors continue to perform well. Additionally, any cuts to guidance or worsening economic indicators could negatively impact sentiment and performance.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The company announced a leadership change, appointing Paul Keel as Chair of the Board. This may signal increased management stability and better decision-making. Additionally, the latest earnings beat supports the positive outlook. There are no new threats identified that could weaken this view.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Continue driving core sales growth across all major businesses and geographies with new product commercialization and customer engagement.
Stated as a priority in 4 of last 4 quarters. Revenue grew from $616.9M in 2025-Q1 to $731M in 2026-Q2, with core sales growth ranging from 5.0% to 10.8% across these quarters. Management has consistently raised full-year outlooks for core sales growth, indicating delivery against this priority.
“We delivered growth across both our reporting segments and all major geographies.”
“All major businesses delivered positive growth, driven by customer engagement and new product commercialization.”
“We delivered 10.8% core revenue growth and positive growth in all major businesses and geographies.”
“We are raising our full year guidance for 2025 based on first half momentum and results.”
Breaks if: Free cash flow remains negative beyond Q1 2026
Breaks if: Share repurchases drop below 1 million shares per quarter
Continue executing on share repurchase programs to return capital to shareholders and manage share count.
Stated as a priority in 3 of last 4 quarters. Share repurchases totaled 2.4 million shares ($59M) in 2026-Q2 and 1.6 million shares ($43M) in 2026-Q1, with an incremental $300 million program authorized. Management is actively executing repurchases, showing delivery on this priority.
“Repurchased 2.4 million shares for approximately $59 million.”
“Repurchased 1.6 million shares for approximately $43 million.”
“Repurchased 1.2 million shares for approximately $24 million.”
Overall, NVST's fundamentals are strong, but the valuation is high compared to peers. The investment thesis will depend on continued execution and sector performance. Not investment advice.